Conservative management of pituitary prolactinomas; evidence for bromocriptine-induced regression.
Thirty-six women with sustained hyperprolactinaemia, 29 showing radiological abnormality of the pituitary fossa, were managed conservatively; 28 accepted bromocriptine treatment which controlled hyperprolactinaemia in all and was associated with improvement in the radiological appearance of the pituitary in 4 cases. Two of the 8 patients who did not accept bromocriptine showed radiological extension of the pituitary lesion; one showed radiological improvement. Bromocriptine should be regarded as a drug to control the pituitary tumour, not merely one which inhibits the endocrine effects.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008598:Menstruation; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D011247:Pregnancy; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D011859:Radiography; D014794:Visual Fields
D001971:Bromocriptine; D011388:Prolactin